Insmed to showcase multiple abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at …

Insmed has announced that it will be showcasing various abstracts on treprostinil palmitil inhalation powder (TPIP) at the Pulmonary Vascular Research Institute (PVRI) 2026 congress in Dublin. These abstracts will cover essential topics such as the Phase 3 PALM-PAH study design, the topline results of the Phase 2b study, a Functional Respiratory Imaging analysis from the Phase 2b study in Pulmonary Arterial Hypertension (PAH), and data on pulmonary vasodilation in rat models.

The presentations at the PVRI 2026 congress will delve into the intricate details of the studies conducted on TPIP to provide a comprehensive understanding of its potential therapeutic benefits. One of the main focuses will be the Phase 3 PALM-PAH study design, which aims to gather critical insights into the efficacy and safety of TPIP in patients with PAH. Additionally, the encore presentation of the Phase 2b study results will further solidify the evidence supporting the use of TPIP as a promising treatment option.

Dr. Martina Flammer, the Chief Medical Officer at Insmed, expressed optimism about the significance of TPIP at the PVRI 2026 congress. She emphasized the importance of the Phase 2b clinical data, advanced imaging analysis, and translational preclinical data in establishing a strong foundation for future Phase 3 programs. The ultimate goal is to enhance patient outcomes and provide a robust treatment alternative for individuals with PAH.

The presentations will cover a wide range of topics, including pulmonary vasodilation with TPIP in rat isolated perfused lungs, the study design of the Phase 3 trial of TPIP in patients with PAH, novel insights from Functional Respiratory Imaging analysis in the Phase 2 study, and an encore presentation of a randomized, double-blind, placebo-controlled study of TPIP in patients with PAH. These presentations will shed light on the potential of TPIP in addressing the unmet needs of patients with PAH.

Treprostinil palmitil inhalation powder (TPIP) is a dry powder formulation developed by Insmed as a once-daily therapy for patients with PAH, PH-ILD, and other rare pulmonary disorders. Administered through a capsule-based inhalation device, TPIP is still under investigation and has not received approval for any indication in any jurisdiction. The Phase 2b study focused on evaluating the efficacy, safety, and pharmacokinetics of TPIP in patients with PAH over a 16-week period, with promising results indicating its potential as a viable treatment option.

PAH is a significant health concern characterized by the narrowing or obstruction of blood vessels in the lungs, resulting in high blood pressure in the pulmonary arteries. TPIP holds promise as a possible solution to improve outcomes for patients with PAH by targeting the underlying causes of the disease and providing a more effective treatment strategy. The research presented at the PVRI 2026 congress will provide valuable insights into the potential of TPIP in revolutionizing the management of PAH.